

Structure, Volume 23


Supplemental Information

Structural Basis of Latrophilin-FLRT-UNC5


Interaction in Cell Adhesion

Yue C. Lu, Olha V. Nazarko, Richard Sando, III, Gabriel S. Salzman, Nan-Sheng Li, Thomas C. Südhof, and Demet Araç


A




B



C



D



E




Figure S1, related to Figure 1

Crystal structure of the isolated FLRT3 LRR, and the crystal lattice of the FLRT3/LPHN3 complex structure.

(A) Ribbon diagram of the isolated human FLRT3 LRR in $P2_1$ space group. Two FLRT3 molecules make an interface on the side surface of FLRT3 where UNC5 binds. The previously reported mouse FLRT3 LRR dimer interface does not exist in our new isolated human FLRT3 structure. (B) Ribbon diagram of the published mouse FLRT3 LRR structure (PDB ID: 4V2E) showing the same interface as in A exists in both isolated FLRT3 structures. (C) Ribbon diagram of the FLRT3/LPHN3 complex structure showing only the FLRT3 LRR. Figure shows the same interface as in A and B also exists in the FLRT3/LPHN3 complex structure. The previously reported FLRT3 LRR dimer interface does not exist in the FLRT3/LPHN3 complex structure. These observations suggest that the observed interface in A,B and C can indeed be the dimer interface. It is also likely that the observed interface is a crystallization artifact that is preferred to generate crystal contacts. Careful mutagenesis experiments will answer these questions. (D) Ribbon diagram showing four FLRT3/LPHN3 complexes in the asymmetric unit of the complex structure. (E) A view of the FLRT3/LPHN3 complex structure crystal lattice.





Figure S2, related to Figure 2


Bio-layer interferometry binding measurement of FLRT3 and LPHN3.

LPHN3 and FLRT3 bind to each other in the nanomolar range. Maximum binding of His-tagged FLRT3 LRR to immobilized biotinylated LPHN3 Olf (A), or His-tagged LPHN3 to immobilized biotinylated FLRT3 LRR (B), measured at steady state during immersion of streptavidin sensor immobilized with biotinylated FLRT3 LRR or biotinylated LPHN3 Olf into various concentrations of His-LPHN3 Olf or His-FLRT3 LRR, respectively. Binding signal was plotted as a function of His-FLRT3 LRR or His-LPHN3 Olf concentration. The dissociation constants were calculated by fitting the curves to a single site binding model using GraphPad Prism.


A Monomeric His-FLRT3 LRR binding to full-length LPHN3 on HEK293 cells (setup for Fig S4)




B Tetramerized His-FLRT3 LRR binding to full-length LPHN3 on HEK293 cells (setup for Fig 3)



C Tetramerized Biotinylated LPHN3 Olf binding to full-length FLRT3 on HEK293 cells (setup for Fig 4 and Fig S5)



D Trimeric complex formation: Tetramerized Biotinylated-LPHN3 Olf binding to HEK293 cells expressing full-length Unc5 via unlabeled FLRT3 LRR (setup for Fig 6C-E, Fig S7)



■ Biotin ■ Neutravidin ● DyLight 650 ● Biotin-Tris-NTA ● His-tag
 ● mouse anti-FLAG antibody ● anti-mouse FITC antibody ● FLAG-tag
 ● mouse anti-c-Myc antibody ● Biotin-Olfactomedin ● c-Myc-tag

Figure S3, related to Figure 3,4 and 6

Experimental Setup for Flow Cytometry experiments

N-terminally tagged full-length proteins (Flag-LPHN3, Myc-FLRT3, His-Unc5D or His-Unc5B) were expressed in HEK293 cells. Cells were then mixed with different combinations of soluble proteins and reagents before performing flow cytometry experiments. Black boxes around proteins or reagents indicate they were pre-incubated before mixing with the other components. Neutravidin is a tetrameric protein with four biotin-binding sites and was used to tetramerize the biotinylated proteins to increase the affinity of the protein due to the avidity effect. Biotin-Tris-NTA is a reagent (kindly provided by the S. Koide lab) to convert His-tagged soluble proteins to biotinylated proteins (It was used when expression/purification of biotinylated proteins was not optimal). Detection of full-length protein expression on the cell surface was monitored by green fluorescence of FITC-conjugated secondary anti-mouse antibody by flow cytometry. Monomeric or tetramerized soluble protein binding to the cells was monitored by red fluorescence of DyLight-conjugated neutravidin by flow cytometry.

- (A) Setup in Figure S4. Monomeric His-FLRT3 LRR binding to HEK293 cells expressing full-length wild type or mutant LPHN3. Biotin-Tris-NTA was used to recognize His tagged FLRT3 LRR.
- (B) Setup in Figure 3. Tetramerized His-FLRT3 LRR binding to HEK293 cells expressing full-length wild type or mutant LPHN3. His-FLRT3 LRR is tetramerized by preincubation with Neutravidin and Biotin-Tris-NTA.
- (C) Setup in Figure 4 and S5. Tetramerized biotinylated-LPHN3 Olf binding to HEK293 cells expressing full-length wild-type or mutant FLRT3. Biotin-tagged LPHN3 Olf was first biotinylated by in vitro biotinylation. Biotinylated LPHN3 Olf is tetramerized by preincubation with Neutravidin.
- (D) Setup for Figure 6 and S7. Tetramerized biotinylated-LPHN3 Olf binding to HEK293 cells expressing full-length wild-type Unc5D or Unc5B. Biotinylated LPHN3 Olf and non-biotinylated His-tagged FLRT3 LRR is tetramerized by preincubation with Neutravidin. The formation of a trimeric complex of His-FLRT3 LRR, biotinylated LPHN3 olf domain and FL-Unc5 expressed by HEK293 cells is observed.

Figure S4, related to Figure 3

Expression and FLRT3 LRR-binding data for all FL-LPHN3 mutants

Wild-type and mutant full-length LPHN3 constructs were tested for surface expression in non-permeabilized HEK293 cells as well as their ability to bind to soluble His-FLRT3 LRR domain using flow cytometry

(A) FL-LPHN3 surface expression in wild-type FL-LPHN3-transfected cells (red) compared to untransfected cells (black), and to mutant FL-LPHN3-transfected cells (blue) (left panels). Non-permeabilized HEK293 cells expressing N-terminally FLAG-tagged FL-Lphn3 were stained with mouse anti-FLAG primary antibody and anti-mouse FITC conjugated secondary antibody. FL-LPHN3 surface expression was measured as green fluorescence from FITC. His-FLRT3 LRR binding to FL-LPHN3-expressing cells was measured by monitoring red fluorescence of DyLight attached to neutravidin (y-axis, right panels). 10 μ M non-tetramerized His-FLRT3 LRR was mixed with the cells, then 100 nM Biotin-Tris-NTA and 100 nM Neutravidin was added for detection of His-FLRT3 LRR binding. Black ovals show the “high LPHN3 expression and high FLRT3 binding” gate. Numbers on the dot plot show percent of events in this gate. (Refer to Figure S3 and Table S3 for detailed experimental setup and experimental conditions)

(B) Surface expression of mutant LPHN3 transfected cells normalized to wild type.

(C) Quantification of cells that fall within the gate of “high LPHN3 expression and high FLRT3 binding” (black ovals) as indicated in A. Bar height represents the percent of cells that fall within the gates shown.






Figure S5, related to Figure 4

Expression and LPHN3 Olf-binding data for all FL-FLRT3 mutants

Wild-type and mutant full-length FLRT3 constructs were tested for surface expression in non-permeabilized HEK293 cells as well as their ability to bind to soluble biotinylated LPHN3 Olf domain using flow cytometry

(A) FL-FLRT3 surface expression in wild-type FL-FLRT3-transfected cells (red) compared to untransfected cells (black), and to mutant FL-FLRT3-transfected cells (blue) (left panels). Non-permeabilized HEK293 cells expressing N-terminally Myc-tagged FL-FLRT3 were stained with mouse anti-c-Myc primary antibody and anti-mouse FITC conjugated secondary antibody. FL-FLRT3 surface expression was measured as green fluorescence from FITC. Biotinylated LPHN3 Olf binding to FL-FLRT3-expressing cells was measured by monitoring red fluorescence of DyLight attached to neutravidin (y-axis, right panels). 100nM purified wild-type biotinylated LPHN3 Olf domain was tetramerized with 100 nM Neutravidin to increase avidity before binding to cells. Black ovals show the “high FLRT3 expression and high LPHN3 binding” gate. Numbers on the dot plot show percent of events in this gate. (Refer to Figure S3 and Table S3 for detailed experimental setup and experimental conditions)

(B) Surface expression of mutant FLRT3 transfected cells normalized to wild type.

(C) Quantification of cells that fall within the gate of “high FLRT3 expression and high LPHN3 binding” (black ovals) as indicated in A. Bar height represents the percent of cells that fall within the gates shown. Separate sets of experiments are indicated by vertical lines. Wild type data is provided as positive control for each dataset.




Figure S6, related to Figure 5

Size-exclusion gel filtration profile showing the formation of FLRT3/LPHN3 complex. Dotted lines represent FLRT LRR dimer and LPHN3 Olf for reference. SDS-Page gel shows fractions corresponding to the complex peak. The elution volumes and corresponding molecular weights for the gel filtration standards are indicated by blue arrows.




Figure S7, related to Figure 6

Formation of a trimeric complex between FLRT3, LPHN3 and Unc5

(A to C) Raw data for Figure 6C to E. Untransfected HEK293 cells or cells transfected with Unc5 were stained with a precomplex of biotinylated LPHN3 Olf domain, unlabeled His-FLRT3 LRR and neutravidin (NAV650) in different combinations to detect binding of LPHN3 Olf to cells with flow cytometry. Unc5D or Unc5B transfected HEK293 cells were tested for binding with 100 nM LPHN3 Olf and wild type FLRT3, or LPHN3 Olf and FLRT-UF mutant precomplex. Panel A data was performed with 5 nM protein concentration with tetramerization, whereas panels B and C were performed with 100 nM protein concentration. Panel A was repeated with 100 nM protein concentration with tetramerization as shown in (D). Similar results were obtained but some non-specific binding is observed when 100 nM concentration was used. See Figure S3 and Table S3 for details about experimental setup and conditions.

Conservation: 7 7 6 9 9 9 6 6 6 7 7 7

human_Lphn3 131 -KVFLCPGLLKGVYQSEHLFESD---HQSGAWCKDPLQAS----DKIYMPWTPYRTDTLLEYSSKDDFI
rat_Lphn1 137 --VFVCPGTLQKVLPTSHESE---HQSGAWCKDPLQAG----DRIYMPWIPYRTDTLLEYASWEDYV
human_Lphn2 133 --IFVCPGTLKAIVDSPCIYEA---QKAGAWCKDPLQAA----DKIYMPWTPYRTDTLLEYASLEDFQ
danio rerio_Lphn3.1 190 -----MPWTPYRTDTLLEYSSKEDFI
myotis lucifugus_Lphn3 4 --VFLCPGLLKGVYQSEHLFESD---HQSGAWCKDPLQAS----DKIYMPWTPYRTDTLLEYSSKDDFI
pelodiscus sinensis_Lphn3 1 --VFLCPGLLKGVYQSEHLFESD---HQSGAWCKDPLQAS----DKIYMPWTPYRTDTLLEYSSKDDFI
human_Myoc 239 GEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTQETTWRIDTVGTDVRQVFEYDLISQFM
macaque_Myoc 226 REGDNGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPYTRETTRIDTVGTDVRQVFEYDLISQFM
xenopus laevis_Olfml3 129 --ITDCSDTISQVTAMKILKRFG---SSAGLWTKDLAGNS----DRIYVFDGAG--NDTVYMYPRMKEFT
human_Noelin-1_ 221 CMQKLACGKLTGISDPVTVKTSG---SRFGSWMTDPLAPEG--DNRVWYMDGY--HNNRFVREYKSMVDFM
human_Noelin-2 189 CAQKLGCGKLTGVSNPITVRAMG---SRFGSWMTDTMAPSA--DSRVWYMDGY--YKGRRVLEFRTLGDFI
rat_Noelin-3 213 CMKKLTCGKLMKITGPIVTVKTSG---TRFGAWMTDPLASEK--NRRVWYMDSY--TNNKIVREYKSIADFV
Consensus_ss: eeeee eeeee eee eeeee eeeee hhhh

Conservation: 99 797 799 9 66 6666 6 6 766 9 77

human_Lphn3 AGR---PTTTYKLPHRVDGTGFVVYDGLFFNKER--TRNIVKFDLRLTRIKSGEAI IANANYHDTSPYRWG
rat_Lphn1 AAR---HTTTYRLPNRVDGTGFVVYDGLFFNKER--TRNIVKFDLRLTRIKSGEAI IANANYHDTSPYRWG
human_Lphn2 NSR---QTTYKLPNRVDGTGFVVYDGLFFNKER--TRNIVKFDLRLTRIKSGEAI INYANYHDTSPYRWG
danio rerio_Lphn3.1 AGR---PTTTYKLPHRVDGTGFVVYDGLFFNKER--TRNIVKFDLRLTRIKSGEAI IANANYHDTSPYRWG
myotis lucifugus_Lphn3 AGR---PTTTYKLPHRVDGTGFVVYDGLFFNKER--TRNIVKFDLRLTRIKSGEAI IANANYHDTSPYRWG
pelodiscus sinensis_Lphn3 AGR---PTTTYKLPHRVDGTGFVVYDGLFFNKER--TRNIVKFDLRLTRIKSGEAI IANANYHDTSPYRWG
human_Myoc QGY---PSKVHILPRPLESTGAVVYSGSLYFQGAE--SRTVIRYELNTEVTKAEKEIPGAGYHGQFPYSWG
macaque_Myoc QGY---PSKVHILPRPLESTGAVVYSGSLYFQGAE--SRTVIRYELNTEVTKAEKEIPGAGYHGQFPYSWG
xenopus laevis_Olfml3 LSSPTRKAAKIRLPPFWIGTGHIVYDGNLYYIRQDNEFQVIKFSLANKTIIDSAVLPIE--QQVPVYGLS
human_Noelin-1 NTD---NFTSHRLPHWSTGQVYVNGSIFYFNKQ--SHIIRFDLKTETILKTRSLDYAGYNNMYAWG
human_Noelin-2 KGQ---NFIQHLLPQPWAGTGHVVYNGSLFYFNKYQ--SNVVVKYHFRSRSVLVQRSLPGAGYNNTFPYSWG
rat_Noelin-3 SGA---ESRTYNLFPKWAGTNHVYVNGSLFYFNKYQ--SNI IKYSFDLGRVLAQRSLEYAGFHNVPYPTWG
Consensus_ss: h eeee eeeee eeeee eeeee eeeeeee ee

Conservation: 7 779 699 99966959 7 7 77 7 967 9 9 9 7 57 79 699 997

human_Lphn3 GKSDIDLAVDENGWLWVIYATEQNNKIVISQLNPYTLRIEGTWDATYDKRSASNAFMICGILYVVKSVYE
rat_Lphn1 GKTIDIDLAVDENGWLWVIYATEGNNGLVVSQNLNPTLRFEGTWTGDKRSASNAFMVCGVLYLRSVYV
human_Lphn2 GKTIDIDLAVDENGWLWVIYATEQNNGMIVISQLNPYTLRFEGTWTGDKRSASNAFMICGILYVVKSVYE
danio rerio_Lphn3.1 GKSDIDLAVDENGWLWVIYATEQNNGRIVVSQNLNPTLRFEGTWDATYDKRSASNAFMICGILYVVKSVYE
myotis lucifugus_Lphn3 GKSDIDLAVDENGWLWVIYATEQNNKIVISQLNPYTLRIEGTWDATYDKRSASNAFMICGILYVVKSVYE
pelodiscus sinensis_Lphn3 GKSDIDLAVDENGWLWVIYATEQNNKIVISQLNPYTLRIEGTWDATYDKRSASNAFMICGILYVVKSVYE
human_Myoc GYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPNENLELEQTWETNIRKQSAANAFIICGTLTYVSSYS-
macaque_Myoc GYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPNENLELEQTWETNIRKQSAANAFIICGTLTYVSSYS-
xenopus laevis_Olfml3 KFNVIDIVADEEGLWVIYATKENEKNICLAKLDPSSLSIEQMWDTPCPIENAESAFVVCGLYVYVNTKL
human_Noelin-1 GHSDIDLAVDEAGLWVIYATNQNAGNIVSRLDPVSLQTLQWNTSYPKRSAGEAFIICGTLTYVNGYS-
human_Noelin-2 GFSDMDFMVDESGLWAVYATNQNAGNIVSRLDPHTLEVMRSWDTGYPKRSAGEAFMIGVLYVTNSHL-
rat_Noelin-3 GFSDIDLMADEIGLWAVYATNQNAGNIVISQLNQDTLEVMKSWSTGYPKRSAGEAFMIGVLYVTNSHL-
Consensus_ss: eeeee eeeee eeeee eeeee hhhheeeeeeeee

Conservation: 6 6 7 9 9 9 6 7997 6 77 967 7 6

human_Lphn3 DDDNEATGNKIDYIYNTDQ--SKDSLVDVFPFNSYQYIAAVDYNPRDNLVWVWNNYHVVKYSLDFGPLDS 396
rat_Lphn1 DDDSEAAGNRVDYAFNTNA--NREPVSLAFPNPYQFVSSVDYNPRDNQLYVWNNYFVVRYSLEFGPPDP 401
human_Lphn2 DNESETGKNSIDYIYNTRL--NRGEYDVFPFNPYQYIAAVDYNPRDNQLYVWNNYFVVRYSLEFGPPDP 397
danio rerio_Lphn3.1 DDDNEALGNKIDYMYNTEK--SRETHLSIPFPNSYQYIAAVDYNPRDNLVWVWNNYHVVIYSLDFGNNDN 414
myotis lucifugus_Lphn3 DDDNEATGNKIDYIYNTDQ--SKDSVVDVFPFNSYQYIAAVDYNPRDNLVWVWNNYHVVKYSLDFGPLDS 268
pelodiscus sinensis_Lphn3 DDDNEATGNKIDYIYNTDQ--SKDSLVDVFPFNSYQYIAAVDYNPRDNLVWVWNNYHVVKYSLDFGPLDS 286
human_Myoc -----SADATVNFAYDTGT--GISKTLTIPFKNRYKYSMIDYNPLEKFLFADNLMVMYTDIKLSKM-- 504
macaque_Myoc -----SADATVNFAYDTGT--GISKTLTIPFKNRYKYSMIDYNPLEKFLFADNLMVMYTDIKLSKM-- 491
xenopus laevis_Olfml3 -----PSRSRIQCVDVSGTISSENVPIVYFPKRYGSHSSMKYNPREKQIYAWDDGYQIIYKLNMKHRDE 390
human_Noelin-1 -----GGTKVHYAYQTNA--STYEYIDIPFQNKYSHISMLDYNPKDRALYAWNNGHQILYNVTLFHVIR 481
human_Noelin-2 -----AGAKVYFAYFTNT--SSYEYTDVFPFHNYSHISMLDYNPRERALYTWNNGHQVLYNVTLFHVIS 449
rat_Noelin-3 -----TGAKVYYSYTKT--STYEYTDIPFHNQYFHSMLDYNARDRALYAWNNGHQVLFNVTLFHIK 473
Consensus_ss: eeeee eee eeee hhh eeeee eeeeeee

Table S1, related to Figure 2

Sequence alignment of Olfactomedin domains

Sequence alignment of olfactomedin domains using PROMALS3D: human LPHN3 (Uniprot ID: Q9HAR2), rat LPHN1 (O88917), human LPHN2 (O95490), *daniorerio* LPHN3.1 (F1QAS7), *myotis lucifugus* LPHN3 (G1P220), *pelodiscussinensis* LPHN3 (K7F4U8), human Myocilin (Q99972), *macaca fascicularis* Myocilin (Q863A3), *xenopus laevis* Olfml3 (B5MFE9), human Noelin1 (Q99784), human Noelin2 (O95897), rat Noelin2 (Q568Y7). The first line in each block shows conservation indices with 9 being the most conserved and 7 and 6 being less conserved. Consensus predicated secondary structures are represented by *h*, alpha-helix, or *e*, beta-strand.

Conservation: 6 9 99969999 9699969 99969 699 6696969
human_FLRT3 1 -----MISAAWSIFLIGTKIGLFLQVAPLSVMAKSCPSVCRCDAGFIYCNDRFLTSIPTGIPEDATTLYL
human_FLRT1 1 -----MDLRDW-LFLCYGLIAFLTEV----IDSTTCPSVCRCDNGFIYCNDRGLTSIPADIPDDATTLYL
human_FLRT2 1 MGLQTTKWPESHGAFFLKSWLIISLGLYSQVSKLLACPSVCRCDRNFVYCNERSLTSVPLGIPEGVTVLYL
danio rerio_FLRT3 1 -----MASNYMSFFVFFIRAGLLGLANPLMTSASCPSQCRCDGTFIYCNDRDLTSPSGIPEDATVLF
xenopus laevis_FLRT3 1 -----MSTETWNLFWAQAQLLLFRISPOYVNAKPCPSVCRCDGGFIYCNDRDLTSPSGIPDDATTLYL
Consensus_ss: hhhhhhhhhhhhhhhhh ee eee eee

Conservation: 69969669969 69 9 6999 9 99999 999 66699996996699 6696 66 696999
human_FLRT3 QNNQINNAGIPSDLKNNLKVRIIYLHNSLDEFPNTLPKYVKELHLQENNIIRTITVYDLSKIPYLEELHL
human_FLRT1 QNNQINNAGIPDLKTKVNVQVIYLYENDLDEFINLPRSLRELHLQDNNVRTIARDSLARIPLEKLHL
human_FLRT2 HNNQINNAGFPAELHNQSVHTVYLYGNQLDEFPMNLKPNVRVHLQENNIQTISRALAQLLKLLELHL
danio rerio_FLRT3 QNNRIKSAGIPTDLRRLNGVEKIYLYCNLDEFPTNPLPNVKELHLQENNIIRTITHASLAQIPFIEELHL
xenopus laevis_FlRT3 QNNQINNAGIPSDLRGLDKVERIYLYRNSLDEFINLKNVKELHLQENNIIRTITVDALSQIPSEELHL
Consensus_ss: hhh eee eee eee hhhhhhhhhhhhe

Conservation: 99996969669669966 969999969999669 999 666999 969996 9 666 9 69 996
human_FLRT3 DDNSVSAVSIIEGAFRDSNYLRLFLSRNHLSTIPWGLPRTIEELRLDDNRISTISSPSLQGLTSLKRLV
human_FLRT1 DDNSVSTVSIIEEDAFADSKQLKLLFLSRNHLSSIPSGLPHTLEELRLDDNRISTIPHLAFKGLNSLRRLV
human_FLRT2 DDNSISTVGVEDGAFREAIISLKLFLSKNHLSSVPVGLPVDLQELRVDENRIAVISDMAFQNLTSERLI
danio rerio_FLRT3 DDNSVSAVSIIEGAFRDSNHLRLFLSRNHLSTIPSGLPMTIEELRFDDNRISSEASLQDLINLKRVL
xenopus laevis_FLRT3 DDNSVSAVSIIEGAFRDNIFLRLFLSRNHLSTIPWGLPRTIEELRLDDNRISTIAEISLQDLTNLKRVL
Consensus_ss: ee hh eee eee ee hhhh eee

Conservation: 699999 9 6666 6 9 696969699999 69 6996 9 69 9969 6 69 666 66 969
human_FLRT3 LDGNLLNHHGLGDKVFNVLNLTSLVRNSLTAAPVNLPGTNLRLKLYLQDNHINRVPPNAFSYLRQLYR
human_FLRT1 LDGNLLANQR IADDTF SRLQNLTELSLVRNSLAAPPNLPSAHLQKLYLQDNAISHIPYNTLAKMRELER
human_FLRT2 VDGNNLTNKGIAEGTFSHLTKLKEFSIVRNSLSHPDPLPGTHLIRLYLQDNQINHIPLTAFSNLRKLER
danio rerio_FLRT3 LDGNLLNRRGIGEMALVNLNLTSLVRNSLTPPANLPGSSLEKLNQDNHINHVPPGAFALRQLYR
xenopus laevis_FLRT3 LDGNLLNNGLGERVFMNLIINLTSLVRNSLTPPANLPGTNLRLKLYLQENHMNVPPNAFADLTQLYR
Consensus_ss: hh eee eee ee hhhh e

Conservation: 99 969 6 96 9 9669 96 69 699999 9 9 6966696 6 699996999696 969966
human_FLRT3 LDMSNNLSNLPOGIFDDLNLITQLILRNNPWYCGCKMKWVRDWLQSLPVKVNVRGLMCQAPEKVRGMAI
human_FLRT1 LDLSNNLTTLPRLGFDLGLNLAQLLRNNPWFCGCLMWRDWDVKARAAVNVVRGLMCQGPVKVRGMAI
human_FLRT2 LDISNNQLRMLTQGVFDNLSNLKQLTARNNPWFCDCKIKWTEWLKYIPSSLNVRGFMCGPEQVRGMAV
danio rerio_FLRT3 LDLSGNNLSSLPMGVFEDLDNLITQLLRNNPWHCNCRMKWVRDWLRTLPKVNVRGFMCGPDKVKGMAI
xenopus laevis_FLRT3 LDMSNNNITALPOGIFDDLNLITQLILRNNPWYCGCKMKWVRDWLQSLPSKVNVRGLMCQAPERVRGMTI
Consensus_ss: ee hhhh eee hhhhhhhhh ee hhh ee

Conservation: 666 66 9 6 9 6 6 666 6 96
human_FLRT3 KDLNAELFDCKDSG-----IVSTIQITTAIPNTVYPAQGWPAVTKQPDIKNPKLTKDHQT 402
human_FLRT1 KDITSEMDECFETGPGGV-----ANAAAKTTASNHASATTPQGSFLTAKAKRPLRPLDSNIDYPM 402
human_FLRT2 RELNMNLLSCPTTTPGLPLFPAPSTASPTTQPPTLSIPNPSRSYTPPTP---TTSKLPTIPDWDGRERV 417
danio rerio_FLRT3 KDLSTELFGCSDTE-----IPTTYE-TSTVSNLTPPSRPQWPSYVTKRPVVKGPDGLGRNYRS 401
xenopus laevis_FLRT3 KDLNKELFDCKDRI-----GSNTIHTTTVLNLSLLPAQGWVVPVTKQPEIRPPDINKIFRT 402
Consensus_ss: ee hhh eee ee

Table S2, related to Figure 2

Sequence alignment of LRR repeats of FLRT homologs

Sequence alignment of FLRT3 LRR domains using PROMALS3D: human FLRT3 (Uniprot ID: Q9NZU0), *xenopus laevis* (B7ZR53), *danio rerio* (B8A507), human FLRT2 (O43155), and human FLRT1 (Q9NZU1). The first line in each block shows conservation indices with 9 being the most conserved and 7 and 6 being less conserved. Consensus predicated secondary structures are represented by h, alpha-helix, or e, beta-strand.

Experiment purpose	Scheme	Data	Reagents used				
			primary antibody	secondary antibody		Fluorophore	
Cell-surface expression							
FLAG-LPHN3 full length	-	Fig 3, S4	mouse anti-FLAG 1:1000	anti-mouse FITC 1:100		FITC	
Myc-FLRT3 full length	-	Fig 4, S5	mouse anti-c-Myc 1:20	anti-mouse FITC 1:100		FITC	
Detect soluble protein binding to cells			neutravidin DyLight 650	biotin-tris-NTA	Biotinylated-LPHN3 Olf	His-FLRT3 LRR	
monomeric His-FLRT3 LRR	Fig S3A	Fig S4	100 nM	100 nM	-	10 μ M	DyLight 650
tetramerized His-FLRT3 LRR	Fig S3B	Fig 3	100 nM	100 nM	-	100 nM	DyLight 650
tetramerized Biotinylated-LPHN3	Fig S3C	Fig 4; Fig S5	100 nM	-	100 nM	-	DyLight 650
Trimeric complex Unc5/FLRT3/LPHN3	Fig S3D	Fig 6C, S7A/ Fig 6D-E, S7B-D	5 nM/ 100 nM	-	5 nM/ 100 nM	5 nM/ 100 nM	DyLight 650

Table S3. Related to Figures 3,4,6,S3,S4,S5,S7. Summary of experimental conditions for flow cytometry.

Table showing experimental conditions used for performing the flow cytometry experiments in the related figures. Experimental conditions for both detecting cell-surface expression and for detecting soluble protein binding to surface expressed proteins are summarized. The schematic diagram explaining the experiment and the data related to the experiment are indicated in separate columns.

Supplementary Methods

Vector and Cloning

For crystallization and protein purification, the LRR repeats of human FLRT3 (residues K29-D357; Uniprot ID: Q9NZU0) was cloned into the XmaI and Not I sites of the pAcGP67a. The olfactomedin domain of human LPHN3 (residues V132-G392; Uniprot ID: Q9HAR2) was cloned into the BamHI and XbaI sites of pAcGP67a. Similarly, the Ig-like domain of mouse Unc5D (residues G49-Q161; Uniprot ID: Q6UXZ4) was cloned into BamHI and NotI sites of pAcGP67a. A His8 tag or biotin tag was added at the C terminus for affinity purification. For mammalian expression and functional analysis, full length human FLRT3 (residues S30-S649), human LPHN3 (residues F20-L1447), and human Unc5B (G27-E934; Uniprot ID: Q8IZJ1), and mouse Unc5D (S46-L884) constructs with preprotrypsin leader sequence containing N-terminal myc, FLAG, His and His-tags, respectively, were cloned into pCMV5 plasmid using Gibson Assembly (NEB). Site directed mutagenesis for FLRT3 and LPHN3 mutants was performed using the Qiagen QuikChange Mutagenesis (QIAGEN).

Protein Expression and Purification

Spodoptera frugiperda (Sf9) cells (Life Technologies) were transfected with pAcGP67a carrying the gene and linearized baculovirus DNA (BestBac 2.0, v-cath/chiA deleted; Expression Systems) using Cellfectin (Life Technologies). Baculovirus was amplified in Sf9 cells in 10%(v/v) fetal bovine serum containing SF900-II SFM medium (Life Technologies).

Large-scale protein expression was performed by infection of *Tri choplusiani* (Hi5) cells in Insect-Xpress medium (Lonza) at a cell density of 2×10^6 cells/ml with an infection course of 72hr. The secreted, glycosylated recombinant proteins were purified using nickel-nitrilotriacetic agarose resin (QIAGEN) and size exclusion chromatography (Superdex 200 10/300 GL; GE) in HBS buffer (10mM HEPES (pH7.2), 150mM NaCl). FLRT was concentrated to 15mg/ml in 10kDa Centricon (Millipore) at 12°C and used for crystallization trials. It was observed that FLRT at high concentration tends to precipitate at 4° C, displaying a white cloudy color. However, precipitation was reversible when concentrated FLRT was warmed up to room temperature.

For FLRT/LPHN3 complex crystallization, purified FLRT and LPHN3 were mixed at 1:1.2 ratio. The complex was purified by size-exclusion chromatography in buffer containing 10mM HEPES (pH7.2), 150 mM NaCl and concentrated to 20 mg/ml in 10 kDa Centricon (Millipore) at 12°C.

For BLITZ and some flow cytometry experiments FLRT3 LRR and LPHN3 Olf were cloned into a pACGP67a vector that carries a C-terminal Avi-tag (sequence GLNDIFEAQKIEWHE) followed by a 6XHis tag. The purified Avi-tagged proteins were biotinylated *in vitro* with purified BirA enzyme that recognizes the Avi-tag and biotinylates it.

Crystallization, Data Collection, and Processing

Prior to crystallization, purified proteins were incubated with carboxypeptidase A (1:100 enzyme to protein ratio; Sigma-Aldrich) and carboxypeptidase B (1:100 enzyme to protein ratio; EMD Millipore) to cleave off the C-terminal residues such

as the His8 tag. Initial screens for crystallization of FLRT and FLRT-LPHN3 complex were carried out using 96-well format kits (Qiagen JCSG Core Suites 1-IV; Rigaku Wizard Crystallography Screens) on a Mosquito Crystal robot (TTP Labtech) at room temperature. Crystals of FLRT3 grew in D10 well of JCSG Core III suite (0.1M Tris pH7, 50% (v/v) PEG200) within 10days. Crystals were cryoprotected by transferring the crystals into mother liquor with 35 % glycerol. The best crystals diffracted to $d_{min}=2.6 \text{ \AA}$.

Similarly, crystallization trials for the FLRT/LPHN3 complex were obtained with 96-well screens. Initial crystal hit was observed in E7 well of Wizard Cubic LCP Block (Rigaku) containing 10% (w/v) PEG 3000, 100 mM MES pH6.0, 200 mM Lithium sulfate. To further optimize, 20 mg/ml protein complex in 10 mM HEPES pH7.2, 150 mM NaCl was mixed with equal volume of mother liquor, and equilibrated against 500 ul mother liquor in a 24-well format. Crystals grew to full size within 4 days and were cryoprotected with 20% glycerol. Many crystals displayed an intergrowth of two separate crystals in a variety of specific configurations, resulting in crystal twinning. The best crystals diffracted to $d_{min}=2.6 \text{ \AA}$.

Structure Determination and Refinement of FLRT3 and FLRT3/LPHN3 complex

Diffraction data was collected at Advanced Photon Source of the Argonne National Laboratories beamline 23-IBD and 19-BM. Data sets were processed using HKL2000. FLRT3 structure was solved by molecular replacement with Phaser-MR (Phenix) using a model of FLRT structure (PDB ID 4V2E). Similarly, FLRT3/LPHN3

structure was determined by molecular replacement using a homology model of the LPHN3 Olfactomedin domain based on the myocilin olfactomedin domain crystal structure (PDB ID 4WXQ). For both structures, refinement was performed in phenix.refine (Phenix) with noncrystallographic symmetry (NCS) restraints. Olf structure in the complex was further refined using LPHN3 olf structure (PDB 5AFB). Since FLRT3/LPHN3 complex crystal displayed twinning, twin law of $h, -k, -l$ was employed throughout the entire refinement process. Minor adjustments of the model were performed manually using COOT, followed by another round of refinement in Phenix. The final FLRT3/LPHN3 model contains four N-linked NAG carbohydrate moieties attached to each chain of the FLRT molecules in the FLRT3/LPHN3 complex structure. PISA program in the CCP4 package was used to analyze the structure such as calculation of the interface area and the hydrogen bonding interactions.

Flow cytometry

Cell culture

HEK293 cell line (ATCC; a generous gift from S. Koide lab) was cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% FBS (Gemini Bio-Products) at 37°C in 5% CO₂ humidified incubator. To seed for transfection cells were washed with PBS buffer and trypsinized (0.05% Trypsin-EDTA; Invitrogen). Cells were transiently transfected with Fugene 6 (PRE2693, Promega) at 60-70% confluence.

Sample preparation

HEK293 cells were transfected with 2 μg of DNA /well in 6-well plates using Fugene6. After 48 hrs of incubation, cells were detached with citric saline solution and washed with PBS and PBS+0.1% BSA (Bovine serum albumin, A3803, Sigma). The pellet was then stained with primary antibodies (in PBS+0.1% BSA) for 30 min (with rotation at room temperature), washed twice with PBS+0.1% BSA and incubated with secondary antibodies for another 30 min and washed twice again. Pellets were resuspended in PBS+0.1% BSA. Flow cytometry data were collected on Guava EasyCyte flow cytometer (10000 events measured).

Cell labeling

To test LPHN3 WT and mutants expression, cells were stained with mouse anti-FLAG M2 antibodies, 1:1000 (F3165, "Sigma"). Fluorescence was determined by incubating with anti-mouse FITC, 1:100 (F0257, "Sigma"). For binding assays purified monomeric His-FLRT LRR was added to primary antibodies to final concentration 10 μM ; 100 nM precomplex of BTtrisNTA - NeutrAvidinDyLight 650 (NAV650) (84607, "Thermo Scientific") was used for fluorescent labeling. Otherwise cells were incubated with tetramerized His-FLRT LRR as a component of 100 nM precomplex HIS-FLRT3 LRR – NAV650 – BTtrisNTA. BTtrisNTA (biotinylated tris-nitrilotriacetic acid) – a reagent that effectively noncovalently biotinylates any poly-His-tagged protein - was generously provided by S. Koide lab.

To test FLRT3 WT and mutant expression, cells were stained with mouse anti c-Myc antibodies (9E10, "DSHB") 1:20 and anti-mouse FITC, 1:100. 100 nM

pretetramerized biotin-LPHN3 olf - NAV650 was used to test binding. Pretetramerization was done by mixing and incubating the reagents for 30 minutes. For Unc5 FLRT3 binding assays, cells transfected with Unc5B and Unc5D constructs as well as untransfected cells were stained with 100nM pretetramerized NAV650 – biotin-LPHN3 olf - His-FLRT3 LRR or NAV650 – biotin-LPHN3 olf - HIS-FLRT3-UF LRR.

Flow cytometry analysis

Sample analysis was performed using FlowJo Single Cell Analysis software and presented as histograms (for protein expression data) and dot plots (an overlay of two fluorescent signals which correspond for protein expression and binding). Also protein expression was presented as diagrams of mean fluorescence intensity for each sample. Gates were set to define a population of cells to show binding.

Bio-layer Interferometry Binding Measurement

Binding between FLRT3 and LPHN3 was performed using the BLITZ system (forteBio). FLRT3 or LPHN3 was then immobilized onto streptavidin sensors, and the unbound protein was washed off by HBS buffer (10mM HEPES pH7.2, 150mM NaCl). The sensor was then immersed into solutions containing immobilized protein's binding partner at various concentrations for 200s. Dissociation was carried out by immersion of sensor into HBS for 250s. Since LPHN3 failed to dissociate completely from the sensor, 3M MgCl₂ in HBS was used to regenerate the streptavidin sensor for 250s. The regeneration solution (3M MgCl₂ in HBS) was

tested multiple rounds prior to the binding experiment to ensure it did not cause any undesired effects on the ligand or sensor chip.

Differential scanning fluorimetry

Differential scanning fluorimetry (DSF) assays were performed on a *CFX384™* (Bio-Rad). Prior to DSF assays, proteins were purified using Gel Filtration chromatography in a buffer containing 10mM HEPES pH 7.2 and 150mM NaCl. After gel filtration, samples were equilibrated to 25°C. A 1:1000 dilution of SYPRO Orange (Invitrogen Molecular Probes) was used as a reporter dye to monitor the denaturing process of the proteins. Samples were assayed on a 384-well plate with final protein concentrations of 6 µM. The temperature was raised with a step of 0.5 °C per minute from 25 °C to 95 °C, collecting fluorescence readings at the end of each interval. Each sample was run in quadruplicate. Collected data was analyzed by *CFX-Manager™* from Bio-Rad. The negative temperature derivative of the fluorescence intensity was plotted as a function of temperature. The temperature corresponding to the minimum value of each curve reflects the midpoint of a two-state transition from folded to unfolded protein. This temperature was thus reported as the melting temperature of the protein (T_m).

Cell aggregation assays

FreeStyle HEK293 cells (Life Technologies) grown to a density of 1×10^6 cells/mL in a 30mL volume were co-transfected with 30µg of either pCMV-Emerald or pCMV-dsRed and 30µg of the indicated construct using FreeStyle Max reagent (Life

Technologies). Cells were grown at 37°C/8%CO₂ with shaking at 125rpms. All cDNAs were driven by the CMV promoter. Transfected cells were mixed in a 1:1 ratio two days post-transfection and incubated for an additional 2 days. Live cells were imaged by dropping 100µL of cell suspension onto a glass slide (FisherBrand). Aggregation index was calculated as shown previously (Boucard et al. 2013. J. Cell Biol.).